A CMV blood test checks whether you’ve been infected with cytomegalovirus, a common virus that most people carry without ever knowing it. The test looks for either antibodies your immune system made in response to the virus or the virus’s genetic material itself. Which version your doctor orders depends on why you’re being tested: pregnancy concerns, an organ transplant, a weakened immune system, or symptoms in a newborn.
What CMV Is and Why It Matters
Cytomegalovirus is a member of the herpes virus family, and like other herpes viruses, it stays in your body permanently once you’re infected. Most healthy adults never notice any symptoms. The virus only becomes a serious concern in specific situations: during pregnancy (when it can pass to the fetus), after an organ transplant (when immune-suppressing medications let the virus reactivate), or in people whose immune systems are already compromised by illness.
Two Types of CMV Blood Tests
Antibody Testing (IgG and IgM)
The most common CMV blood test measures antibodies, the proteins your immune system produces to fight the virus. Two types of antibodies are checked, each telling a different part of the story.
A positive CMV IgG result means you were infected with CMV at some point in your life. It doesn’t tell you when. For anyone 12 months or older, a positive IgG simply confirms past exposure. A negative IgG means you’ve likely never been infected and are still susceptible to a first-time infection.
CMV IgM antibodies suggest a more recent infection, but the picture is less straightforward. IgM can show up during a brand-new infection, a reactivation of an old one, or a reinfection with a different strain. So a positive IgM alone isn’t enough to confirm a first-time infection. When doctors need to distinguish a new infection from a reactivation, they use an additional test called IgG avidity. Low avidity combined with a positive IgM is considered reliable evidence that the infection is new.
Results that fall in an equivocal or borderline range can occur during early infection or from nonspecific reactions in the lab. These typically require repeat testing.
PCR (Viral Load) Testing
A PCR test detects the virus’s actual DNA in your blood and measures how much is present. This is the test used most often for transplant recipients and people with weakened immune systems, where the goal isn’t just knowing whether CMV is present but tracking how actively it’s replicating.
Viral load numbers help doctors decide when to start antiviral treatment, whether the treatment is working, and when it’s safe to stop. Both the absolute number and the trend matter. A rapidly rising viral load signals greater risk of the virus causing organ damage, even if the number hasn’t reached a high threshold yet. Conversely, a single low-level result (under a few hundred copies per milliliter) doesn’t always mean disease is developing. Persistently elevated numbers or a viral load that rises again after initially dropping can be a sign the virus is becoming resistant to treatment.
CMV Testing During Pregnancy
Routine CMV screening during pregnancy is not recommended in the United States. The reasons are practical: current antibody tests can be difficult to interpret, they can’t reliably predict whether the fetus will actually become infected, and treatment options for fetal infection remain limited.
That said, testing may be ordered if a pregnant woman develops symptoms consistent with CMV, such as prolonged fever, fatigue, or swollen glands. The stakes are highest during a first-time infection in the first trimester, when the risk of complications to the fetus is greatest. Transmission rates from mother to baby run 30 to 40% in the first and second trimesters and climb to 40 to 70% in the third trimester. A woman experiencing a reactivation or reinfection is less likely to transmit the virus to her baby than someone with a primary infection, though it’s still possible.
One important limitation: up to 28% of pregnant women with a confirmed primary infection never develop detectable IgM antibodies, meaning a negative IgM result during pregnancy doesn’t completely rule out a new infection.
Testing Newborns for Congenital CMV
When a baby is born with signs that could point to congenital CMV, such as a small head size, jaundice, rash, low birth weight, an enlarged liver or spleen, seizures, or eye damage, testing needs to happen quickly. Urine is the preferred sample, though saliva or blood can also be used. The critical window is within two to three weeks of birth. Testing after that point can’t reliably distinguish a congenital infection (present before birth) from one picked up during or shortly after delivery.
Monitoring After Organ Transplant
Transplant recipients face a particularly high risk of CMV reactivation because the medications that prevent organ rejection also suppress the immune system. For these patients, PCR viral load testing is performed on a regular schedule, typically weekly for the first 12 to 16 weeks after transplant.
This monitoring strategy, called preemptive therapy, works by catching the virus early. Rather than giving every transplant patient antiviral medication from the start, doctors watch the viral load and begin treatment only when the numbers cross a threshold. Treatment continues, with weekly viral load checks, until the virus drops below detectable levels. The specific cutoff varies by lab and testing platform, but the principle is consistent: track the trend, treat when needed, and confirm the virus is suppressed before stopping medication.
What To Expect From the Test
A CMV blood test is a standard blood draw. No fasting or special preparation is needed. For antibody testing, results are typically reported as positive, negative, or equivocal, sometimes with a numerical index where values of 1.1 or above are considered positive. PCR results come back as a viral load number, often reported in copies per milliliter or international units per milliliter.
A positive IgG on its own is not a cause for alarm. It means your body encountered CMV at some point, which is true for roughly half of all adults by age 40. The result becomes clinically meaningful mainly in the context of pregnancy planning, transplant matching, or immune suppression. If you’re a healthy adult with a positive IgG and no symptoms, it generally requires no follow-up.